Olema Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Olema Pharmaceuticals, Inc. on January 27, 2026, reporting events occurring on January 30, 2026. The filing addresses the departure of a senior executive and the appointment of an interim successor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Separation Payment: $621,283 lump-sum payment to the departing officer.
- Payment Breakdown: $562,640 (12 months base salary), $23,443 (pro-rated 2026 target bonus), and $35,200 (COBRA health insurance premiums).
Material Changes
The primary material change is the departure of Shane Kovacs, Chief Operating and Financial Officer, effective January 30, 2026. The filing explicitly states the departure is not due to any disagreement regarding financial operations, policies, or practices.
Outlook, Management Commentary, and Risks
Interim Leadership: Sean Bohen, M.D., Ph.D., the Chief Executive Officer, has assumed the role of Principal Financial Officer on an interim basis until a successor is appointed.
Transition Plan: Mr. Kovacs will serve as a consultant through August 1, 2026, during which his outstanding equity awards will continue to vest.
Risks/Contingencies: The company is currently conducting a search for a permanent Chief Financial Officer.
Investor Verification Checklist
- Confirm the timeline for the appointment of a permanent Chief Financial Officer.
- Review the Separation and Consulting Agreement (Exhibit 10.1) for specific conditions attached to the lump-sum payment and consulting role.
- Monitor future filings for any changes in financial reporting oversight during the interim period.
- Verify the status of Mr. Kovacs' equity awards and vesting schedule post-departure.